Heptares Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heptares Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014060
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heptares Therapeutics Ltd (Heptares), a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise StaR technology, StaR-driven X-ray crystallography, Biophysical Mapping and StaR fragment screening. Heptares’ products are used in the treatment of Alzheimer’s disease, schizophrenia, binge eating, type 2 diabetes, autism, depression, dyskinesia, migraine treatment, and others. The company partners with other pharma and biotech companies to develop its products. Heptares is headquartered in Welwyn Garden, the UK.

Heptares Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Partnerships 13
Heptares Therapeutics Enters into Research Agreement with Juntendo University 13
Heptares Therapeutics and PeptiDream Enter into Agreement 14
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 15
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 16
Jitsubo Enters into Agreement with Heptares Therapeutics 17
Heptares Therapeutics and leadXpro Enter into Agreement 18
Heptares Therapeutics to Form Partnership with Kymab 19
Heptares Therapeutics Enters into Agreement with Pfizer 20
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
AstraZeneca Enters Into Co-Development Agreement With Heptares 25
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 27
Licensing Agreements 28
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
Allergan Amends Licensing Agreement with Heptares Therapeutics 29
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 30
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 31
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 32
Acquisition 34
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 34
Sosei Acquires Heptares Therapeutics for USD400 Million 35
Heptares Therapeutics Ltd – Key Competitors 36
Heptares Therapeutics Ltd – Key Employees 37
Heptares Therapeutics Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Government and Public Interest 39
May 31, 2017: Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 39
Dec 08, 2016: Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family 40
Dec 08, 2016: Sosei subsidiary Heptares scientists solve structure of CCR9 Chemokine receptor offering unique opportunity to apply structurebased design across Chemokine receptor 41
Apr 25, 2016: Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease 42
Jan 11, 2016: Tetragenetics Awarded $1.5M Research and Development Grant by NIH 43
Product News 44
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 44
Clinical Trials 45
Apr 05, 2017: Heptares to Receive US$12 Million Milestone Payment from Astrazeneca 45
Jul 06, 2016: Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca 46
Feb 10, 2016: Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia 47
Other Significant Developments 48
Feb 02, 2016: Heptares Launches “Orbit” Initiative – A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS) 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heptares Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Heptares Therapeutics Enters into Research Agreement with Juntendo University 13
Heptares Therapeutics and PeptiDream Enter into Agreement 14
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 15
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 16
Jitsubo Enters into Agreement with Heptares Therapeutics 17
Heptares Therapeutics and leadXpro Enter into Agreement 18
Heptares Therapeutics to Form Partnership with Kymab 19
Heptares Therapeutics Enters into Agreement with Pfizer 20
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
AstraZeneca Enters Into Co-Development Agreement With Heptares 25
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 27
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
Allergan Amends Licensing Agreement with Heptares Therapeutics 29
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 30
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 31
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 32
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 34
Sosei Acquires Heptares Therapeutics for USD400 Million 35
Heptares Therapeutics Ltd, Key Competitors 36
Heptares Therapeutics Ltd, Key Employees 37
Heptares Therapeutics Ltd, Subsidiaries 38

★海外企業調査レポート[Heptares Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cisco Systems, Inc.:企業のM&A・事業提携・投資動向
    Cisco Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cisco Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • LifeScan Inc-医療機器分野:企業M&A・提携分析
    Summary LifeScan Inc (LifeScan), a subsidiary of the Johnson & Johnson, develops, manufactures and markets blood glucose monitoring solutions for hospital and home use. The company’s product portfolio includes blood glucose meters; test strips and control solutions; lancing devices; diabetes managem …
  • Strategic Oil & Gas Ltd (SOG):企業の財務・戦略的SWOT分析
    Summary Strategic Oil & Gas Ltd (Strategic Oil & Gas) is an upstream oil and gas exploration and development company. The company acquires, explores, operates, manages, and develops crude oil and natural gas assets. It holds interests and operates its oil and gas exploration projects such as Marlowe …
  • Litgrid AB (LGD1L):企業の財務・戦略的SWOT分析
    Litgrid AB (LGD1L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析
    Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • JRI Orthopaedics Ltd:企業の製品パイプライン分析2018
    Summary JRI Orthopaedics Ltd (JRI) a subsidiary of Orthopaedic Research UK (ORUK), is a manufacturer of orthopaedic implants and surgical instruments. The company develops products for joint replacement, repair and reconstruction. It offers products for shoulder and knee arthoplasty, besides customi …
  • Ferring International Center SA:企業の戦略的SWOT分析
    Ferring International Center SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • National Bank of Canada:企業の戦略・SWOT・財務分析
    National Bank of Canada - Strategy, SWOT and Corporate Finance Report Summary National Bank of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Banco Bradesco SA:企業の戦略・SWOT・財務情報
    Banco Bradesco SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bradesco SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Merus Labs International Inc (MSL):企業の財務・戦略的SWOT分析
    Summary Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women's health, urology, and i …
  • Tervita Corp
    Tervita Corp - Strategy, SWOT and Corporate Finance Report Summary Tervita Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. ValiRx uses GeneICE technology, which enables silen …
  • Avadel Pharmaceuticals Plc (AVDL)-製薬・医療分野:企業M&A・提携分析
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, CNS (narcolepsy), pain, respiratory diseases and diabetes. The company’s product portfolio includes Bloxiverz, Karbinal ER, …
  • Huttig Building Products Inc:企業の戦略・SWOT・財務情報
    Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report Summary Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • A.P. Eagers Limited:企業の戦略・SWOT・財務情報
    A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report Summary A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kingspan Group Plc:企業のM&A・事業提携・投資動向
    Kingspan Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kingspan Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • The Nature’s Bounty Co:企業の戦略的SWOT分析
    The Nature's Bounty Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Rottneros AB (RROS):企業の財務・戦略的SWOT分析
    Rottneros AB (RROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • BBB Technologies Inc:製品パイプライン分析
    Summary BBB Technologies Inc (BBB Tech) is a development stage medical technology company, which develops devices and applications that facilitate the early diagnosis of metabolic and cardiovascular disorders. It develops single-drop, mobile integrated diagnostic tools for blood testing. Its lead pr …
  • ProAxsis Ltd:企業の製品パイプライン分析2018
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆